Retatrutide: Evidence, Phase 3 Trials & Australian Regulatory Status (2026)

Overview: Evidence-led overview of retatrutide (LY3437943): mechanism, Phase 2 peer-reviewed data, 2026 Phase 3 topline results, safety signals and current Australian regulatory status.

Last reviewed and source-checked: 6 October 2026. Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that activates three metabolic hormone receptors: GIP, GLP-1 and glucagon. It is being studied for obesity, type 2 diabetes and obesity-related complications. It is not approved by the TGA for routine supply in Australia and should not be confused with an approved medicine.

What is retatrutide?

Retatrutide is a once-weekly investigational peptide engineered to stimulate the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. The research rationale is that combining these three pathways may influence appetite, glucose regulation and energy expenditure through complementary mechanisms.

The compound is often described as a triple agonist. That description refers to its receptor pharmacology, not to regulatory approval or proven superiority over approved treatments.

What has been shown in peer-reviewed human research?

The human evidence now includes both the 2023 Phase 2 trial and the peer-reviewed TRIUMPH-1 Phase 3 trial published online in the New England Journal of Medicine on 29 September 2026. The Phase 2 study The study enrolled 338 adults with obesity or overweight plus at least one weight-related condition.

At 48 weeks, mean body-weight change was dose-dependent, ranging from approximately 8.7% at the lowest studied dose to 24.2% in the 12 mg group, compared with 2.1% with placebo. Gastrointestinal adverse events were the most common and were generally more frequent at higher doses. Dose-dependent increases in heart rate were also reported.

Primary source: Jastreboff et al., NEJM 2023, DOI 10.1056/NEJMoa2301972

What changed on 29 September 2026?

TRIUMPH-1 moved from sponsor-reported topline evidence to a peer-reviewed Phase 3 publication. In the treatment-regimen analysis, mean body-weight change at 80 weeks was −17.6%, −23.7% and −25.0% in the 4 mg, 9 mg and 12 mg groups, compared with −3.9% with placebo.

Earlier headlines used Lilly’s efficacy estimand, which reported −28.3% for the 12 mg group. The figures answer different analytical questions: the treatment-regimen estimand includes outcomes regardless of discontinuation or prohibited additional interventions, while the efficacy estimand estimates results had participants remained on assigned treatment without those interventions.

Primary record: TRIUMPH-1 Phase 3 paper, PMID 42814954

Current clinical-trial programme

Retatrutide is being studied across multiple Phase 3 trials. One example is TRIUMPH-3 (ClinicalTrials.gov identifier NCT05882045), evaluating retatrutide in people with obesity and cardiovascular disease. As of the latest public record, that study is active and no longer recruiting.

ClinicalTrials.gov: NCT05882045

Safety: what is known and what is not?

In the Phase 2 obesity trial, the most common adverse events were gastrointestinal and were dose-related. Heart-rate increases were also observed. Larger Phase 3 programmes are intended to provide a more complete picture of common and uncommon adverse events, discontinuation rates and longer-term outcomes.

Important unknowns remain. Retatrutide is still investigational, the full programme has not completed regulatory review, and unapproved products sold online may not contain the substance or concentration claimed on the label. A Victorian Chief Health Officer alert reported six acute liver-injury cases associated with unapproved products labelled retatrutide, while a later TGA test found one product contained semaglutide and no retatrutide. These alerts concern unapproved labelled products, not verified clinical-trial material.

Australian regulatory status

The Therapeutic Goods Administration has specifically named retatrutide among unapproved peptide products of concern. In 2026 the TGA and Australia’s Chief Medical Officer warned about serious adverse events associated with unapproved peptide products and emphasised that products not included in the Australian Register of Therapeutic Goods have not been evaluated by the TGA for safety, quality or effectiveness.

The TGA also states that advertising retatrutide to the Australian public as a therapeutic good is prohibited because it is unapproved. Elite Peps Australia therefore presents retatrutide only as a subject of scientific and regulatory reporting and does not sell, promote or recommend it for use.

TGA: public-health risks associated with unapproved peptide products, 19 June 2026

TGA: advertising GLP-1 receptor agonists and retatrutide

For a separate safety-surveillance signal, see our analysis of NSW ED presentations mentioning unapproved peptide use; triage mentions do not establish product identity or causation.

Choose the right retatrutide guide

• Live trial tracker: dated trial results, estimands, publications and programme changes.
• “GLP-3” and Australian status: terminology, approval and TGA context.
• TGA counterfeit alert: the September tested-product incident.
• This profile: mechanism, evidence hierarchy and research limits.

How to interpret the evidence

Established in monitored trials: Retatrutide produced substantial mean weight reduction in peer-reviewed Phase 2 and TRIUMPH-1 Phase 3 studies.

Still investigational: Publication does not equal approval. Indications, labelling and the overall risk–benefit assessment remain matters for regulators.

Not established: The long-term risk-benefit profile, final regulatory indications, approved prescribing information, and the quality or identity of unapproved products sold outside regulated medicine supply chains.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972.
2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published online 29 September 2026. DOI: 10.1056/NEJMoa2604169.
3. Eli Lilly and Company. TRIUMPH-1 Phase 3 topline results. 21 May 2026.
4. ClinicalTrials.gov. NCT05882045, TRIUMPH-3.
5. Therapeutic Goods Administration. Concerns regarding the public health risks associated with unapproved peptide products. 19 June 2026.

Editorial note: This page is educational and reports on published research and regulatory information. It is not medical advice and does not provide instructions for obtaining, preparing, dosing or using retatrutide.